Trial Profile
Efficacy, safety and 10-year cardiovascular disease risk reduction of alirocumab and evolocumab therapy in addition to maximal tolerated cholesterol lowering therapy in patients with hypercholesterolemia and cardiovascular disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Jul 2017
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary) ; Evolocumab (Primary)
- Indications Hypercholesterolaemia
- Focus Adverse reactions; Therapeutic Use
- 05 Jul 2017 New trial record